Valeant Pharmaceuticals is a publicly traded pharmaceutical company based in Montreal, Canada. The company has a diverse product portfolio with focus on branded pharmaceuticals, branded generics and over-the-counter products. It has specialization in dermatology, eye health, neurology and consumer healthcare. In addition, Valeant Pharmaceuticals has a portfolio of more than 500 products from its prior history as a group of specialty chemical and radiochemical research, development and supply companies.
One of the growth strategy for Valeant has been acquisitions, sometimes in the multi-billion dollar range, of medical and pharmaceutical companies. This year itself Valeant Pharmaceuticals completeed its acquisition of substantially all the assets of Dendreon Corporation, including worldwide rights to PROVENGE, an immunotherapy treatment for advanced prostate cancer. As of July 2015, the company was valued at over $116 billion by market capitalization, making it the largest public company in Canada and the largest pharmaceutical company in the nation.
- Cesamet (nabilone)
- Ribavirin (licensed to Schering Plough)
|Traded as||NYSE: VRX
S&P/TSX 60 component
|Founder||August and Marie Krogh|
|Headquarters||Laval, Quebec, Canada|
|Key people||J. Michael Pearson (Chairman & CEO)
Howard B. Schiller (CFO)
|Products||Cesamet (nabilone), Efudex, Mestinon, Diastat, Ribavirin (licensed to Schering Plough), CeraVe|
|Revenue||US$2.73 billion (Q2 2015|
|Number of employees||NA|
|Subsidiaries||Bausch & Lomb, Salix Pharmaceuticals, Medicis Pharmaceutical, Solta Medical, Dendreon, OraPharma, Obagi|